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Abstract	
Electronic	medical	records	from	first	opinion	equine	veterinary	practice	
may	represent	a	unique	resource	for	epidemiologic	research.	The	
appropriateness	of	this	resource	for	risk	factor	analyses	was	explored	as	
part	of	an	investigation	into	clinical	and	pharmacologic	risk	factors	for	
laminitis.	Amalgamated	medical	records	from	seven	UK	practices	were	
subjected	to	text	mining	to	identify	laminitis	episodes,	systemic	or	intra-
synovial	corticosteroid	prescription,	diseases	known	to	affect	laminitis	
risk	and	clinical	signs	or	syndromes	likely	to	lead	to	corticosteroid	use.	
Cox	proportional	hazard	models	and	Prentice,	Williams,	Peterson	models	
for	repeated	events	were	used	to	estimate	associations	with	time	to	
first,	or	subsequent	laminitis	episodes,	respectively.	Over	seventy	
percent	of	horses	that	were	diagnosed	with	laminitis	suffered	at	least	
one	recurrence.	Risk	factors	for	first	and	subsequent	laminitis	episodes	
were	found	to	vary.	Corticosteroid	use	(prednisolone	only)	was	only	
significantly	associated	with	subsequent,	and	not	initial	laminitis	
episodes.	Electronic	medical	record	use	for	such	analyses	is	plausible	
and	offers	important	advantages	over	more	traditional	data	sources.	It	
does,	however,	pose	challenges	and	limitations	that	must	be	taken	into	
account,	and	requires	a	conceptual	change	to	disease	diagnosis	which	
should	be	considered	carefully.	
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1.	Introduction	
Laminitis	is	a	painful,	prevalent,	multifactorial	condition	of	ungulates.	In	the	
domestic	horse,	compromised	welfare	due	to	the	pain	and	immobility	associated	
with	laminitis	often	leads	to	euthanasia	(Slater,	2014,	Wylie	et	al.,	2013a	and	
Wylie	et	al.,	2013b).	Many	studies	have	identified	significant	risk	factors	for	
laminitis,	but	have	not	always	been	in	agreement	(Hunt,	1993,	Polzer	and	Slater,	
1997,	Slater	et	al.,	1995,	Wylie	et	al.,	2013a	and	Wylie	et	al.,	2013b).	
Administration	of	certain	systemic	corticosteroids	has	been	presumed	to	pose	a	
risk	of	laminitis,	but	this	potentially	putative	risk	factor	has	not	been	well	studied	
in	the	general	horse	population	(Bailey	and	Elliott,	2007,	Bailey,	2010,	French	et	
al.,	2000,	Katz	and	Bailey,	2012	and	McCluskey	and	Kavenagh,	2004).	Given	
financial	constraints	and	ethical	implications,	previous	studies	have	often	been	of	
limited	sample	size,	thus	reducing	the	power	of	the	analyses	to	detect	significant	
relationships	of	small	effect	size.	In	addition,	the	recurrent	nature	of	laminitis	
has	not	been	fully	taken	into	account.	It	is	possible	that	the	initial	case	of	
laminitis	is	associated	with	different	risk	factors	compared	to	subsequent	
episodes.	
	
The	use	of	electronic	medical	records	(EMR)	in	first-opinion	equine	veterinary	
medicine	in	the	UK	is	widespread.	Although	amalgamation	of	records	between	
practices	for	epidemiologic	research	purposes	is	somewhat	rare	at	present,	
sharing	of	such	data	will	become	more	common	in	future	(Johns	and	Adams,	
2015	and	Wylie	et	al.,	2014).	This	resource	can	offer	huge	sample	sizes,	and	
could	be	more	easily	extrapolated	to	the	general	horse	population	compared	
with	other	study	types.	It	may,	however,	suffer	from	problems	not	usually	
encountered	in	prospective	studies,	due	to	record	accuracy	and	completeness,	
for	example.	In	first-opinion	practice,	diagnoses	and	case	management	decisions	
are	often	informed	by	less	than	the	full	battery	of	gold-standard	tests	available	
for	each	condition.	Indeed,	veterinarians	in	practice	are	often	required	to	treat	
horses	according	to	tentative	diagnoses	reached	by	pattern	recognition	alone,	or	
with	minimal	investigation,	due	to	financial,	time,	or	practical	constraints.	In	
addition,	free-text	medical	records	vary	greatly	in	verbosity	between	individuals,	
cases	and	practices.	EMR	offer	a	true	historical	account	of	the	decisions	made	in	
the	treatment	of	individual	animals,	whether	those	decisions	were	well-founded	
or	otherwise.	As	such,	EMR	are	a	very	different	data-type	compared	with	
experimental	data,	where	exhaustive	exclusion	criteria	can	be	universally	
applied.	EMR	likely	contain	a	wealth	of	useful,	accurate	information,	but	may	
require	a	lower	sensitivity	of	case	identification	to	be	of	used.	
	
The	aims	of	this	study	were	to	use	a	large	database	of	first-opinion	electronic	
medical	records	to	analyse	the	relationships	between	known	medical	risk	factors	
for	the	first,	and	subsequent	episodes	of	laminitis.	Our	hypotheses	were	that	(a)	
systemic	corticosteroid	administration	is	significantly	and	independently	
associated	with	laminitis	risk,	and	(b)	significant	risk	factors	for	initial	and	
subsequent	laminitis	episodes	will	vary.	
	
Ethical	approval	for	this	study	was	granted	by	the	Research	Ethics	Committee,	
School	of	Veterinary	Medicine,	University	of	Glasgow.	
	
2.	Materials	and	methods	
2.1.	Data	source	
	
EMR	from	a	convenience	sample	of	seven	first-opinion	equine	veterinary	
practices	around	the	UK	were	collected	and	amalgamated	into	a	single	
anonymised	dataset	(Table	1).	These	data	spanned	twenty-six	years	(1987–2013,	
n	=	70481	records),	and	contained	the	following	database;	unique	numeric	
identifier	per	horse,	date	of	birth,	date	of	entry	into	the	system	(date	of	
veterinary	record),	breed	and	sex.	Free-text	notes	detailing	the	reason	for	the	
consultation,	clinical	findings,	presumptive	or	definitive	diagnosis,	treatment,	
and	prescription	information	were	available	for	each	record.	Age	was	calculated	
as	the	date	of	record	minus	the	date	of	birth,	and	ages	less	than	0	or	greater	
than	40	years	(due	to	erroneous	date	records	in	16%	of	records)	were	removed.	
Age	was	subsequently	categorised	as	follows:	under	1	year,	1–4	years,	4–8	years,	
8–13	years	and	above	13	years.	Sex	was	converted	in	to	three	categories:	female,	
male,	and	unknown	sex.	Breeds	were	converted	initially	into	ten	categories;	
Arab/Arab	cross,	Cob/Cob	cross,	Draught/Draught	cross,	Native/Native	cross,	
pony/pony	cross,	Thoroughbred/Thoroughbred	cross,	Warmblood/Warmblood	
cross,	Welsh/Welsh	cross,	unknown	and	other	breed.	Horses	were	followed	from	
their	first	record	in	the	dataset,	to	their	first	or	subsequent	laminitis	episodes,	or	
until	they	died,	were	lost	from	follow	up	or	the	study	period	ended.	Censoring	
was	assumed	to	be	uninformative.	All	analyses	were	conducted	in	R	statistical	
environment	(R	Core	Team,	2015).	Statistical	significance	was	set	at	0.05	and	all	
testing	was	two-tailed.	
	
Table	1.	
Description	of	the	convenience	sample	of	first-opinion	equine	veterinary	practices	throughout	the	UK	that	
contributed	data	to	the	current	study	between	1987	and	2013.	
Practice	
Number	of	full	
time	
veterinarians	 Location	
Cover	own	
out-of-hours	
RCVS	
Accrediteda	
Species	
seen	
Number	of	
branches	
Number	of	
records	
1	 11	 Scotland	 Yes	 Yes	 Mixed	 2	 2893	
2	 21	 Central	
England	
Yes	 Yes	 Equine	
only	
1	 38705	
3	 17	 Northern	
England	
Yes	 Yes	 Mixed	 5	 1442	
4	 14	 Central	
England	
Yes	 No	 Mixed	 4	 14339	
5	 11	 Southern	
England	
Yes	 No	 Equine	
only	
1	 5565	
6	 4	 Northern	
England	
Yes	 Yes	 Large	
species	
1	 5052	
7	 8	 Northern	
England	
Yes	 No	 Mixed	 2	 2485	
a	Accreditation	of	the	practice	by	the	Royal	College	of	Veterinary	Surgeons,	URL:	
http://www.rcvs.org.uk/practice-standards-scheme/.	
	
2.2.	Text	mining	
Text	mining	was	employed	to	convert	free	text	records	into	numeric	variables.	
Commercially	available	text	mining	software	(SimStat	and	WordStat,	Provalis	
Research	Ltd.,	Canada)	was	used	to	construct	dictionaries	of	words	or	phrases	
designed	to	mine	free	text	records	for	instances	of	systemic	or	intra-synovial	
corticosteroid	administration	(triamcinolone	acetonide,	dexamethasone,	
prednisolone	and	methylprednisolone)	and	laminitis,	and	for	records	of	
syndromes	known	to	be	related	to	laminitis,	or	known	to	be	a	common	
indication	for	systemic	or	intra-synovial	corticosteroid	use	(Table	2).	These	
syndromes	were	decided	upon	a	priori	after	discussion	with	experienced	equine	
veterinarians,	and	examination	of	a	proportion	of	EMR	containing	corticosteroid	
administration.	The	iterative	mining	process	used	was	similar	to	that	published	in	
Lam	et	al.,	2007;	and	validated	for	use	in	veterinary	data	by	Anholt	et	al.	(	Anholt	
et	al.,	2014a,	Anholt	et	al.,	2014b	and	Lam	et	al.,	2007).	Negated	terms	were	
excluded	where	possible	(e.g.	‘not	Cushing’s	disease’).	A	‘case’	of	laminitis	or	
disease	was	thereby	defined	as	a	record	containing	at	least	one	non-negative	
word	or	phrase	pertaining	to	that	condition.	
	
Table	2.	
Examples	of	the	words	and	phrases	used	to	categorise	electronic	medical	records	(EMR)	from	a	convenience-
sampled	UK	horse	cohort	between	1987	and	2013.	Where	possible	common	negations	were	excluded,	and	all	
terms	were	validated	through	assessment	of	the	term	in	context.	
Category	 Examples	of	words/phrases	used	for	case	detection	(excluding	misspellings)	
Laminitis	 Laminitis,	founder,	laminitic	
Triamcinolone	 Adcortyl,	Triamcinolone,	Kenalog,	Vetalog	
Recurrent	Airway	
Obstruction	(RAO)	
RAO,	heaves,	Chronic	Obstructive	Pulmonary	Disease	(COPD)	
Respiratory	 Bronchospasm,	bronchoconstriction,	cough,	dyspnoea,	pneumonia,	wheeze	
Dermatologic	 Abrasion,	alopecia,	blepharitis,	bursitis,	cellulitis,	Chorioptes,	dermatitis,	eczema,	
folliculitis,	furunculosis,	lymphangitis,	pyoderma,	sweet	itch,	thrombophlebitis	
Equine	Metabolic	
Syndrome	(EMS)	
EMS,	metabolic	syndrome,	peripheral	Cushing’s	
Pituitary	Pars	 Cushing’s	disease,	PPID,	hyperadrenocorticism,	Pergolide,	Prascend	
Intermedia	
Dysfunction	(PPID)	
Prednisolone	 Prednicare,	Prednidale,	Prednisolone,	Preds	
Methylprednisolone	 Depomedrone,	Methylprednisolone	
Dexamethasone	 Colvasone,	Dexamethasone,	Dexadresson,	Dexafort,	Duphacort	
Gastrointestinal	 Colic,	colitis,	diarrhoea,	enteritis,	enterocolitis,	scour	
Systemic	 Abortion,	allergy,	anaphylaxis,	autoimmune,	bacteraemia,	dystocia,	endometritis,	
endotoxaemia,	hepatitis,	mastitis,	Pemphigus,	peritonitis,	placentitis,	pyelonephritis,	
pyrexia,	sepsis,	toxaemia,	urticaria,	vasculitis	
Orthopaedic	 Osteoarthritis,	epiphysitis,	kissing	spines,	osteomyelitis,	sesamoiditis,	spavin,	spondylosis,	
tendonitis	
Neurological	 Ataxia,	encephalopathy,	hemiplegia,	meningitis,	Wobblers	syndrome	
	
	
2.3.	Outcomes	
	
Two	outcomes	were	assessed	in	this	study,	thus	two	models	were	built.	The	first	
episode	of	laminitis	per	horse	was	the	initial	outcome	examined	(Model	1).	
Subsequent	episodes	of	laminitis	were	examined	as	a	secondary	outcome	
(Model	2).	Horses	were	at	risk	of	a	subsequent	episode	of	laminitis	60	days	
following	the	previous	episode.	A	hypothesised	causal	web	for	the	association	of	
all	factors	involved	in	these	analyses	is	shown	in	Fig.	1.	
	
	
Fig.	1.		
Proposed	causal	web:	possible	relationships	between	reasons	for	corticosteroid	administration,	chronic	diseases	
and	laminitis.	
	
2.4.	Survival	analyses	
	
2.4.1.	First	laminitis	episode	(Model	1)	
	
Univariable	Cox	proportional	hazard	models	were	used	to	estimate	the	
association	between	horse	characteristics,	disease	and	corticosteroid	
administration,	and	time	to	first	laminitis	episode.	A	random	(frailty)	effect	was	
included	to	account	for	clustering	within	practices,	and	models	were	stratified	
according	to	age	group	at	the	time	of	entry	to	the	dataset.	Variables	were	
retained	for	consideration	if	the	Wald	p-value	for	the	coefficient	was	<0.2.	The	
assumption	of	proportional	hazards	was	tested	for	each	variable	by	visual	
inspection	of	scaled	Schoenfeld	residuals	plots.	The	breed	variable	was	re-
categorised	to	leave	only	statistically	significant	levels,	with	others	subsumed	
into	the	‘Unknown/other	breed’	category.	Collinearity	between	potential	risk	
factors	was	assessed	with	Cramer’s	V,	and	where	associations	exceeded	0.4,	the	
variable	with	the	higher	univariable	AIC	was	considered	for	exclusion	from	
further	analyses	(	Rosner	and	Rosner,	2006).	
	
A	forward	stepwise	manual	multivariable	model-building	procedure	was	then	
carried	out,	by	sequential	inclusion	of	significant	variables	in	order	of	ascending	
AIC.	Variables	were	retained	if	coefficient	Wald	p-values	or	the	likelihood	ratio	
test	(LRT)	p-value	for	inclusion	of	the	variable	was	<0.05.	All	pairwise	interactions	
between	retained	variables	were	assessed	for	LRT	significance,	and	were	
included	in	the	final	model	in	order	of	ascending	AIC.	Variables	not	included	
were	subsequently	forced	back	into	the	model	to	assess	the	proportion	change	
in	existing	coefficients.	Variables	were	considered	for	retention	if	they	led	to	a	
change	in	any	existing	coefficients	of	more	than	30%.	The	power	of	the	model	to	
detect	a	postulated	hazard	ratio	of	1.3	for	the	effect	of	corticosteroid	
prescription	(excluding	methylprednisolone)	on	laminitis	risk	at	significance	level	
0.05	was	81%,	96%	and	64%	for	triamcinolone,	dexamethasone	and	
prednisolone,	respectively.	
	
2.4.2.	Subsequent	laminitis	episodes	(Model	2)	
	
To	investigate	the	secondary	outcome,	only	46	horses	had	more	than	6	episodes	
of	laminitis,	so	analysis	of	subsequent	laminitis	episodes	was	restricted	to	the	
second–sixth	episodes	(n	=	37888	records,	3358	horses).	Recurrent	airway	
obstruction	(RAO),	pituitary	pars	intermedia	dysfunction	(PPID)	and	equine	
metabolic	syndrome	(EMS)	were	considered	lifelong	risk	factors	for	laminitis,	
therefore	all	time-points	following	detection	of	these	conditions	in	an	individual	
were	considered	positive	for	that	condition,	irrespective	of	future	diagnoses.	For	
analysis	of	the	time	to	subsequent	laminitis	episode	(second–sixth),	a	recurrent-
events	extension	to	the	Cox	proportional	hazards	model	was	employed.	The	
Prentice,	Williams,	Peterson	(PWP)	model	allows	for	ordered	recurrent	events,	
and	adjusts	for	clustering	and	the	non-independence	of	events	within	individuals	
(	Prentice	et	al.,	1981).	A	frailty	term	was	included	to	account	for	clustering	
within	practices,	and	models	were	stratified	by	age	group.	Univariable	and	
multivariable	model	building	procedures	proceeded	as	above.	Proportional	
hazards	assumptions	for	three	syndromes	were	violated;	the	risk	of	time	to	
subsequent	laminitis	episode	of	PPID,	colic	and	dermatologic	syndromes	was	not	
static	over	time	(and	tended	to	increase	in	all	cases),	therefore	interaction	terms	
with	time	were	added	to	account	for	these	time-varying	covariates.	
	
3.	Results	
3.1.	Population	characteristics	
	
Table	3	reports	the	variables	considered	for	models	of	association	with	time	to	
laminitis	episode.	Dexamethasone	was	the	corticosteroid	prescribed	to	the	
greatest	number	of	horses	(2204,	3.1%),	and	gastrointestinal	syndromes	affected	
the	largest	number	of	horses	of	all	the	disease	syndromes	studied	(7760,	11%).	
Laminitis	was	detected	in	medical	records	of	4081	(5.8%)	horses	(Table	4).	Of	
these,	72%	(2965	horses)	had	more	than	one	laminitis	episode.	The	median	(IQR)	
time	between	first	and	second	episodes	of	laminitis	was	363	days	(133–865).	
Table	5	gives	a	description	of	the	outcomes	tested,	including	their	event	rates.	
	
Table	3.	
Baseline	characteristics	of	a	convenience	sample	of	UK	horses	attended	by	seven	first-opinion	UK	veterinary	
practices	between	1987	and	2013.	
Characteristic	 	
Number	of	
horses	
Percentage	
(n	=	70481)	
Number	of	laminitis-positive	
horses	(%)	
Sex	 Female	 26019	 36.9	 1682	(6.4)	
	 Male	 37975	 53.9	 2101	(5.5)	
	 Unknown	 6487	 9.2	 298	(4.6)	
Practice	 1	 2893	 4.1	 168	(5.8)	
	 2	 38705	 54.9	 2681	(6.9)	
	 3	 1442	 2.0	 82	(5.7)	
	 4	 14339	 20.3	 261	(1.8)	
	 5	 5565	 7.9	 296	(5.3)	
	 6	 5052	 7.2	 417	(8.3)	
	 7	 2485	 3.5	 176	(7.1)	
Breed	 Other/unknown	 59681	 84.7	 3854	(6.5)	
	 Arab	 954	 1.4	 65	(6.8)	
	 Cob	 2132	 3.0	 110	(5.2)	
	 Draught	 1049	 1.5	 38	(3.6)	
	 Native	 2218	 3.1	 227	(10.2)	
	 Pony	 1415	 2.0	 115	(8.1)	
	 Welsh	 3032	 4.3	 305	(10.1)	
Corticosteroids	 Triamcinolone	 1234	 1.8	 38	(3.1)	
	 Dexamethasone	 2204	 3.1	 90	(4.1)	
	 Methylprednisolone	 306	 0.4	 11	(3.6)	
	 Prednisolone	 895	 1.3	 108	(12.1)	
Disease	
syndrome	
Gastrointestinal	 7760	 11.0	 450	(5.8)	
	 Equine	Metabolic	
Syndrome	
143	 0.2	 82	(57.3)	
	 Pituitary	Pars	
Intermedia	
Dysfunction	
2070	 2.9	 601	(29.0)	
	 Recurrent	Airway	
Obstruction	
1228	 1.7	 65	(5.3)	
	 Respiratory	 3773	 5.4	 243	(6.4)	
	 Orthopaedic	 1839	 2.6	 193	(10.5)	
	 Neurological	 631	 0.9	 65	(10.3)	
	 Dermatologic	 4473	 6.3	 323	(7.2)	
	 Systemic	 2778	 3.9	 251	(9.0)	
	
Table	4.	
Number	of	laminitis	episodes	recorded	per	horse	between	1987	and	2013	at	a	convenience	sample	of	seven	UK	
first-opinion	equine	veterinary	practices.	
Total	number	of	laminitis	episodes	 Number	of	horses	 Percentage	of	horses	(n	=	70481)	
0	 66400	 94.21	
1	 1116	 1.58	
2	 2553	 3.62	
3	 79	 0.11	
4	 208	 0.30	
5	 30	 0.04	
6	 49	 0.07	
7	 8	 0.01	
8	 21	 0.03	
9	 4	 0.01	
10	 3	 <0.01	
11	 1	 <0.01	
12	 3	 <0.01	
13	 1	 <0.01	
14	 1	 <0.01	
15	 1	 <0.01	
16	 1	 <0.01	
17	 0	 0	
18	 1	 <0.01	
19	 0	 0	
20	 1	 <0.01	
	
	
Table	5.	
Description	of	the	outcomes	assessed	in	the	current	study	of	first	and	subsequent	laminitis	episodes	in	a	UK	
horse	cohort	between	1987	and	2013.	
Outcome	
Number	of	
horses	(%)	
Number	
of	events	
Range	
of	
events	
Median	follow-up	time	
(days)	(IQR)	
Total	
time	
Event	rate	per	1000	horse	
years	(95%	CI)	
First	
laminitis	
episode	
3977	(5.7)	 3977	 NA	 901	(84–3480)	 23597.4	
years	
168.5	(163.8–173.4)	
All	laminitis	 3977	(5.7)	 8168	 0−20	 1188	(87–4343)	 50783.2	 160.8	(157.7–164.1)	
episodes	 years	
	
IQR	Inter-quartile	range;	CI	confidence	interval.	
	
	
3.2.	First	laminitis	episode	(Model	1)	
	
Table	6	reports	significant	associations	between	risk	factors	and	the	time	to	first	
laminitis	episode.	Compared	to	unknown/other	breeds,	Arabs,	cobs,	Native	
breeds,	ponies	and	Welsh	breeds	were	associated	with	time	to	first	laminitis	
episode.	Of	all	syndromes	studied,	only	neurological	syndromes	were	not	
associated	with	time	to	first	laminitis	episode.	Administration	of	systemic	
corticosteroids	was	not	significantly	associated	with	time	to	the	first	laminitis	
episode.	A	number	of	significant	interaction	terms	were	included	in	the	final	
model	for	first	laminitis	episode	(see	Table	6).	Triamcinolone	prescription	was	
not	significant	in	a	univariable	model	(p-value	0.84),	and	no	methylprednisolone	
was	prescribed	during	the	time	from	study	entry	to	first	laminitis	episode	for	any	
horse.	Dexamethasone	and	prednisolone	prescription	were	significant	in	
univariable	models	(p-values	<	0.01),	but	were	dropped	from	the	multivariable	
model	after	inclusion	of	disease	and	signalment	variables.	
	
Table	6.	
Association	between	potential	risk	factors	and	time	to	first	laminitis	episode	in	a	veterinary-attended	UK	horse	
cohort	between	1987	and	2013.	Hazard	ratios	are	derived	from	Model	1,	a	multivariable	Cox	survival	analysis	of	
time	to	first	laminitis	episode.	
Characteristic	 	
Number	of	
horses	
Hazard	
Ratio	
95%	Confidence	
Interval	
Wald	p-
value	
Breed	 Unknown/other	 59681	 1	(REF)	 	 	
	 Arab	 954	 1.80	 1.37–2.34	 <0.01	
	 Cob	 2132	 1.36	 1.10–1.69	 <0.01	
	 Draught	 1049	 0.94	 0.66–1.33	 0.72	
	 Native	 2218	 2.46	 2.10–2.87	 <0.01	
	 Pony	 1415	 1.77	 1.43–2.20	 <0.01	
	 Welsh	 3032	 2.56	 2.23–2.94	 <0.01	
Disease	
syndrome	
Pituitary	Pars	Intermedia	Dysfunction	
(PPID)	
2070	 11.18	 9.26–13.51	 <0.01	
	 Equine	Metabolic	Syndrome	(EMS)	 143	 8.06	 5.79–11.20	 <0.01	
	 Gastrointestinal	 7760	 2.57	 2.22–2.98	 <0.01	
	 Orthopaedic	 1839	 1.85	 1.59–2.16	 <0.01	
	 Dermatologic	 4473	 3.70	 3.03–4.52	 <0.01	
	 Systemic	 2778	 1.35	 1.19–1.53	 <0.01	
	 Respiratory	 3773	 1.17	 1.04–1.32	 <0.01	
	 Recurrent	Airway	Obstruction	(RAO)	 1228	 1.44	 1.21–1.70	 <0.01	
Sex	 Female	 26019	 1	(REF)	 	 <0.01	
	 Male	 37975	 0.88	 0.82–0.94	 <0.01	
	 Unknown	 6487	 0.65	 0.55–0.76	 <0.01	
PPID:	time	 	 	 0.99	 0.99–0.99	 <0.01*	
Colic:	time	 	 	 0.99	 0.99–0.99	 <0.01*	
Dermatologic:	
time	
	 	 0.99	 0.99–0.99	 <0.01*	
Breed:	
dermatologic	
Other/unknown:	Dermatologic	 	 1	(REF)	 	 <0.01*	
	 Arab:	Dermatologic	 	 0.28	 0.11–0.69	 <0.01	
	 Cob:	Dermatologic	 	 0.51	 0.27–0.95	 <0.01	
	 Draught:	Dermatologic	 	 0.27	 0.10–0.78	 <0.01	
	 Native:	Dermatologic	 	 0.45	 0.25–0.82	 <0.01	
	 Pony:	Dermatologic	 	 0.17	 0.04–0.71	 <0.01	
	 Welsh:	Dermatologic	 	 0.22	 0.12–0.40	 <0.01	
PPID:	EMS	 	 	 0.35	 0.21–0.57	 <0.01*	
PPID:	
Orthopaedic	
	 	 0.51	 0.35–0.72	 <0.01*	
EMS:	
dermatologic	
	 	 0.31	 0.12–0.78	 <0.01*	
	
REF	referent	level.	
	
*	
p-values	from	likelihood-ratio	tests	comparing	models	with	and	without	interaction	term.	
	
	
3.3.	Subsequent	laminitis	episodes	(Model	2)	
	
Table	7	contains	all	variables	significantly	associated	with	the	risk	of	second–
sixth	laminitis	episode	in	a	multivariable	PWP	model.	Horse	breed	and	sex	were	
not	associated	with	subsequent	laminitis	episodes.	Prednisolone	prescription	
was	associated	with	5.3	times	the	hazard	of	subsequent	laminitis	episodes,	and	
unlike	the	first	laminitis	episode,	neurological	syndromes	were	associated	with	
an	increased	hazard	also.	RAO	was	associated	with	a	reduced	hazard	of	
subsequent	laminitis	episodes,	in	contrast	to	its	increased	hazard	ratio	for	first	
laminitis	episode.	Methylprednisolone	prescription	was	not	associated	with	
subsequent	laminitis	at	the	univariable	stage.	All	other	excluded	variables	were	
significant	at	univariable	modelling	stage,	then	dropped	at	the	multivariable	
modelling	stage.	
	
Table	7.	
Association	between	risk	factors	and	time	to	subsequent	laminitis	episode	(second–sixth	episodes,	n	=	3358	
horses)	in	horses	receiving	veterinary	attention	from	a	convenience	sample	of	UK	veterinary	practices	between	
1987	and	2013.	Results	of	Model	2,	a	multivariable	Prentice,	Williams	Peterson	model	of	time	to	second–sixth	
laminitis	episode.	
Characteristic	
Number	of	
Horses	
Hazard	
Ratio	 95%	Confidence	Interval	
Wald	p-
value	
Pituitary	Pars	Intermedia	Dysfunction	(PPID)	 721	 1.63	 1.31–2.03	 <0.01	
Orthopaedic	 256	 5.33	 3.48–8.18	 <0.01	
Respiratory	 383	 3.10	 2.08–4.62	 <0.01	
Systemic	 358	 2.69	 1.84–3.93	 <0.01	
Prednisolone	 156	 5.25	 2.59–10.63	 <0.01	
Neurological	 83	 7.20	 3.11–16.67	 <0.01	
Recurrent	Airway	Obstruction	(RAO)	 294	 0.62	 0.45–0.85	 <0.01	
PPID:	Respiratory	 	 4.53	 1.50–13.69	 <0.01*	
PPID:	RAO	 	 2.75	 1.23–6.12	 0.02*	
Systemic:	RAO	 	 7.02	 1.68–29.38	 <0.01*	
*p-values	from	likelihood-ratio	tests	comparing	models	with	and	without	interaction	term.	
	
4.	Discussion	
Risk	factors	for	the	first	(Model	1)	and	subsequent	(Model	2)	episodes	of	
laminitis	were	found	to	differ	in	this	population.	Breed,	sex,	EMS,	colic	and	
dermatologic	syndromes	were	significantly	associated	with	the	first	episode	of	
laminitis,	but	not	subsequent	episodes.	Similarly,	prednisolone	prescription	and	
neurological	syndromes	were	significantly	associated	with	subsequent	laminitis	
episodes,	but	not	with	a	horse’s	first	episode.	Risk	factors	found	to	affect	both	
first,	and	subsequent	laminitis	episodes	were	PPID,	orthopaedic,	systemic,	and	
respiratory	syndromes.	Many	of	the	clinical	syndromes	studied	were	
hypothesized	to	only	affect	laminitis	risk	through	the	intermediary	variable	of	
corticosteroid	prescription	(Fig.	1),	however	this	was	not	supported	by	the	final	
models	reported	here.	This	finding	may	indicate	that	laminitis	has	more	potential	
aetiological	origins	than	first	thought,	and	that	corticosteroid	use	is	less	
important.	
	
Recurrence	of	laminitis	was	common	in	this	population,	with	72%	of	laminitic	
horses	experiencing	at	least	one	recurrence	of	the	condition.	Laminitis	is	
clinically	subdivided	into	acute	and	chronic	forms,	the	former	of	which	can	be	
recurrent	and	cause	no	permanent	anatomic	changes,	and	the	latter	of	which	is	
defined	by	irreversible	hoof	changes	and	worsening	prognosis	(Hunt,	1993,	Katz	
and	Bailey,	2012	and	Slater	et	al.,	1995).	Detection	of	these	subdivisions	requires	
radiography,	and	progression	from	acute	to	chronic	stage	occurs	at	
unpredictable	times,	if	at	all.	In	the	majority	of	cases,	the	stage	of	laminitis	was	
not	reported	in	EMR,	therefore	this	subdivision	was	not	available	for	inclusion	in	
the	modelling	procedures.	
	
EMR	represent	an	important	data	resource	for	veterinary	epidemiology.	
Embedded	systematic	clinical	nomenclature	systems	are	not	yet	a	feature	of	
most	practice	management	software	systems,	thus	all	disease	and	treatment	
information	(excluding	auto-generated	prescriptions	and	billing)	is	contained	in	
free-text.	The	largest	source	of	error	in	the	use	of	this	information	arises	through	
the	necessity	to	apply	text-mining	or	machine	learning	technologies	to	categorise	
records,	as	manual	classification	would	be	too	cumbersome	and	thereby	negate	
the	sample-size	benefits	of	EMR.	Record	categorisation	is	unlikely	to	reach	100%	
sensitivity	and	specificity	because	of	the	variation	in	nomenclature,	phraseology,	
spelling	accuracy	and	verbosity	of	EMR.	However,	with	judicious	use	of	powerful	
software,	and	an	iterative,	diligent	approach,	diagnostic	accuracy	of	the	text-
mining	process	for	medical	data	has	been	shown	to	be	highly	accurate,	especially	
in	the	case	of	pharmacology	(Anholt	et	al.,	2014a,	Anholt	et	al.,	2014b	and	Roque	
et	al.,	2011).	The	second	large	source	of	potential	error	in	the	use	of	EMR	from	
first-opinion	practice	arises	from	the	variable,	reactive	nature	of	primary	
veterinary	care.	Whereas	in	prospective,	experimental	studies,	inclusion	criteria	
can	and	must	be	exhaustive,	retrospective	‘real-world’	data	will	likely	never	
reflect	such	completeness.	The	role	of	the	veterinarian	is	to	deliver	the	most	
likely	diagnosis	possible,	given	financial	and	practical	constraints,	and	to	offer	the	
most	appropriate	care	for	that	individual.	In	reality,	diagnoses	are	commonly	
arrived	at	without	a	full,	referral-level	battery	of	appropriate	tests.	Treatment	
and	management	regimens	vary	greatly,	even	given	seemingly	identical	clinical	
scenarios.	EMR	therefore	represent	historical	accounts	of	the	true	course	of	
clinical	events,	and	when	the	general	veterinary-attended	population	is	the	
population	of	interest,	study	of	the	decisions	made	in	the	‘real	world’	may	be	
more	applicable	than	experimental	data.	This	study	was	based	upon	data	from	a	
convenience	sample	of	practices,	which	may	have	led	to	a	reduction	in	the	
generalizability	of	results,	however,	given	that	each	practice	offered	primary	care	
to	the	general	horse	population,	this	reduction	should	be	small.	
	
The	EMR	used	in	this	study	had	some	limitations.	In	very	many	cases,	the	
diagnostic	criteria	employed	to	make	clinical	decisions	were	missing,	partial,	or	
unclear.	Application	of	stringent	diagnostic	inclusion	criteria	was	therefore	not	
possible	if	the	data	were	to	be	used	to	greatest	effect.	The	diagnoses	included	in	
this	study	were	therefore	taken	as	rote,	either	from	non-negative	terminology	
inclusions,	or	prescription	of	medications	that	were	very	likely	to	indicate	disease	
diagnosis	(e.g.	Pergolide	use	as	an	indicator	of	PPID).	In	addition,	many	of	the	
diseases	studied	are	unchallenging	to	diagnose	in	a	primary	care	setting,	simply	
by	pattern	recognition	of	the	combination	of	history	and	clinical	signs	presented,	
thus	lending	confidence	to	included	diagnoses.	We	cannot,	however	be	certain	
of	the	accuracy	of	this	method,	without	retrospectively	obtaining	definitive	
diagnoses,	which	were	not	possible	given	data	anonymization	and	ethical	
considerations.	Different	practices,	and	veterinarians	working	‘in	the	field’	as	
opposed	to	a	hospital	setting,	will	have	employed	differing	diagnostic	modalities	
in	laminitis	case	investigation.	We	posit,	however,	that	a	diagnosis	of	laminitis	
made	through	clinical	examination	with	or	without	radiography	alone	is	likely	to	
be	sufficiently	accurate	(given	that	this	will	be	the	basis	for	treatment	in	a	great	
many	animals)	to	allow	case	identification	in	this	study.	Therefore,	although	
other	diagnostic	investigations	would	offer	more	information	on	the	disease	
course,	the	diagnosis	without	such	information	is	valid	and	worthy	of	inclusion.	
Most	clinical	scenarios	were	grouped	into	‘syndromes’	for	use	here,	to	enable	
inclusion	of	clinical	signs	likely	to	lead	to	corticosteroid	administration	before	
definitive	diagnoses	were	reached.	Given	these	differences,	apparent	disease	
prevalence	reported	here	cannot	be	directly	compared	to	other	studies.	No	
husbandry	or	environmental	details	were	included	in	EMR,	therefore	known	
laminitis	risk	factors	related	to,	for	example,	grain	overload,	could	not	be	
included	in	the	models.	Some	errors	were	detected	in	either	the	date	of	
veterinary	care	episode,	or	date	of	birth	of	some	horses	(16%	of	records).	It	was	
not	possible	to	identify	which	dates	were	erroneous,	therefore	calculated	ages	
with	spurious	values	were	set	as	missing.	We	had	no	reason	to	believe	that	date	
errors	would	systematically	over	or	underestimate	horse	ages,	and	had	no	way	
of	retrospectively	validating	dates	resulting	in	appropriate	ages,	therefore	age	
was	included	in	the	analyses,	but	conclusions	drawn	from	it	must	be	interpreted	
cautiously.	Horses	were	anonymised	and	given	a	unique	numeric	identifier	
before	analyses	proceeded.	Given	that	registration	at	multiple	veterinary	
practices	is	possible,	some	duplication	or	truncation	of	medical	histories	may	
have	occurred,	but	given	the	geographic	spread	of	the	practices	involved	this	
was	thought	likely	to	be	minimal.	For	similar	reasons,	laminitis	or	other	disease	
diagnoses	(or	corticosteroid	administration)	may	have	occurred	prior	to	an	
animal’s	inclusion	in	these	data.	All	horses	were	considered	at	risk	of	laminitis,	
provided	it	was	more	than	sixty	days	since	their	last	episode.	This	time	period	
was	chosen	as	it	was	thought	likely	that	a	horse	suffering	an	active	episode	of	
laminitis	would	receive	veterinary	products	or	attention	at	least	once	in	a	two-
month	period.	There	are	no	previous	studies	from	which	to	validate	this	
assumption,	however,	therefore	it	may	be	an	over	or	underestimate.	EMS,	PPID	
and	RAO	are	lifelong	conditions	known	to	increase	laminitis	risk	(McCue	et	al.,	
2015,	Menzies-Gow,	2015	and	Tadros	and	Frank,	2013).	Horses	with	these	
diagnoses	may,	therefore,	have	been	under	greater	scrutiny	for	signs	of	laminitis,	
and	apparent	prevalence	may	therefore	have	been	inflated	in	these	animals.	
Changes	over	the	study	period	in	the	prevalence	of	diagnosis	of	each	condition	
should	not	have	materially	affected	the	estimates	of	strength	of	association	with	
laminitis	due	to	the	nature	of	survival	analysis.	
	
The	clinical	syndromes	tested	for	association	with	laminitis	in	this	study	
represent	many	of	the	clinical	scenarios	encountered	in	primary	practice,	that	
are	either	known	or	thought	to	pose	an	increased	risk	of	laminitis	(e.g.	
endometritis),	or	are	indications	for	the	use	of	corticosteroids.	Without	inclusion	
of	the	possible	causes	of	corticosteroid	use,	spurious	associations	between	drug	
use	and	laminitis	may	have	been	generated.	Despite	the	inclusive,	general	terms	
used	to	categorise	EMR,	inclusion	of	disease	syndromes	led	to	corticosteroid	use	
dropping	out	of	significance	in	most	multivariable	models.	Respiratory	
syndromes	and	RAO	were	included	as	separate	risk	factors	in	this	study.	
Corticosteroids	are	often	administered	to	ease	inflammation-related	respiratory	
clinical	signs	in	the	absence	of	definitive	diagnoses.	Respiratory	signs	such	as	
cough,	dyspnoea	and	wheezing	can	be	associated	with	multiple	diseases.	RAO	
represents	a	specific	clinical	entity,	which	theoretically	poses	a	lifelong	risk	of	
laminitis	due	to	its	corticosteroid-based	treatments,	or	possibly	due	to	the	
effects	systemic	inflammation	(Cornelisse	and	Robinson,	2013	and	Menzies-Gow,	
2015).	RAO	was	included	separately	so	that,	as	with	PPID	and	EMS,	diagnosis	of	
these	conditions	would	render	an	animal	permanently	categorised	as	suffering	
from	that	condition,	unlike	other	transient,	curable	respiratory	conditions.	The	
Cramer’s	V	statistic	for	association	between	respiratory	and	RAO	categories	was	
0.09	(data	not	shown),	indicating	sufficiently	low	association	to	include	both	as	
independent	predictors.	
	
Four	corticosteroid	drugs	were	included	in	these	analyses,	due	to	their	
commonness	in	practice	and	their	systemic	or	intra-synovial	routes	of	
administration.	These	four	drugs	have	been	found	to	exert	different	effects	upon	
equine	tissues,	have	different	pharmacologic	properties,	and	could	therefore	be	
supposed	to	have	different	associations	(if	any)	with	laminitis	risk	(Cornelisse	and	
Robinson,	2013	and	McIlwraith,	2010).	Specific	drug	formulations	were	not	
always	included	in	EMR,	and	accurate	doses	and	anatomic	sites	of	administration	
were	vanishingly	rare.	Most	horses	in	the	primary	care	setting	are	not	weighed	
regularly,	and	drug	dosing	tends	to	be	calculated	based	on	the	veterinarian’s	
best	guess	of	an	animal’s	weight.	Therefore,	given	the	paucity	of	accurate	
information	available,	drug	dose	was	not	included	in	these	analyses.	Only	the	use	
of	prednisolone	remained	in	the	multivariable	Model	2	after	accounting	for	
significant	signalment	and	clinical	parameters,	and	despite	a	relatively	low	model	
power	(64%).	This	suggests	that	triamcinolone,	dexamethasone	and	
methylprednisolone,	used	as	they	were	in	this	population	over	the	study	period,	
do	not	pose	a	risk	of	laminitis	induction	or	recurrence.	The	reason	for	this	
difference	is	unclear,	however	it	may	relate	to	the	differences	in	route	of	
administration;	prednisolone	is	often	administered	orally	in	tablet	form	(Peroni	
et	al.,	2002),	whereas	the	other	corticosteroids	are	more	commonly	delivered	via	
intra-muscular	injection.	A	course	of	prednisolone	tablets	would	therefore	
represent	a	single	prescription,	but	a	much	longer	exposure	time	(through	
multiple	doses)	compared	to	single	injections.	Although	the	potency	of	
triamcinolone	and	dexamethasone	may	be	greater	than	the	equivalent	dose	of	
prednisolone	(Johnson	et	al.,	2002),	given	this	postulated	difference	in	exposure	
time,	the	risk	of	laminitis	following	prednisolone	administration	would	be	
magnified.	It	is	possible	that	the	‘true’	magnitude	of	effect	of	triamcinolone	and	
dexamethasone	on	laminitis	risk	is	significant	(i.e.	over	1),	but	this	study	would	
have	been	underpowered	to	detect	associations	of	less	than	1.3	using	the	Cox	
proportional	hazard	model.	
	
Clinical	risk	factors	for	initial	laminitis	episodes	were	found	to	differ	from	those	
for	subsequent	episodes.	Only	PPID,	orthopaedic,	systemic	and	respiratory	
syndromes	were	found	to	be	associated	with	time	to	laminitis	episode	in	both	
scenarios.	Interestingly,	RAO	appeared	to	be	associated	with	an	increased	risk	of	
the	initial	laminitis	episode,	but	a	reduced	risk	of	subsequent	episodes.	The	
reason	for	this	disparity	is	not	known.	Breed	and	sex	were	important	risk	factors	
for	initial	laminitis	episode,	but	not	for	subsequent	episodes.	Both	breed	and	sex	
have	previously	been	associated	with	laminitis	risk	(Alford	et	al.,	2001,	Bamford	
et	al.,	2014	and	Wylie	et	al.,	2014),	as	have	the	endocrinopathies	PPID	and	EMS	
(Donaldson	et	al.,	2004,	Johnson	et	al.,	2002,	Wylie	et	al.,	2013a	and	Wylie	et	al.,	
2013b).	Many	significant	interaction	terms	were	included	in	both	final	
multivariable	models.	These	terms	were	not	shared	between	both	models,	but	
all	included	either	PPID,	EMS	or	RAO,	which	were	included	as	lifelong	diagnoses	
after	the	initial	diagnostic	record.	All	main	effects	remained	statistically	
significant	despite	the	inclusion	of	interactions.	Interplay	between	clinical	risk	
factors	for	laminitis	is	therefore	very	complex.	Categories	of	clinical	signs	
included	as	predictors	in	these	analyses	were	intended	to	capture	potential	
associations	between	underlying	(unknown)	disease	processes	and	laminitis,	to	
avoid	spurious	associations	of	drug	administration	with	the	outcome.	Therefore,	
greater	emphasis	should	be	placed	on	interpreting	the	presence	or	absence	of	
corticosteroid	administration	predictors	in	final	models,	rather	than	the	
presence,	or	magnitude	of	clinical	sign	risk	factors.	The	only	truly	putative	risk	
factor	with	a	significant	laminitis	risk	association	in	these	models	was	
prednisolone	administration.	This	corticosteroid	should	therefore	be	avoided	in	
horses	with	pre-existing	laminitis	risks	or	those	who	have	already	suffered	from	
the	disease.	Good	management	may	lower	the	risk	of	EMS	(through	
maintenance	of	appropriate	weight),	dermatologic	syndromes	(via	avoidance	of	
injuries	leading	to	cellulitis,	for	example),	or	colic,	but	for	the	most	part,	these	
clinical	conditions	are	unavoidable.	It	was	beyond	the	scope	of	this	study	to	
assess	the	effects	and	appropriateness	of	treatment	of	the	conditions	included	
on	laminitis	risk,	but	future	research	may	be	able	to	ascertain	which	treatment	
regimens	can	modify	the	disease	course	and	offer	hope	of	avoiding	future	
laminitis	episodes.	Similarly,	we	did	not	include	information	on	the	treatment	of	
laminitis	(e.g.	orthopaedic	shoeing,	corrective	farriery,	nutritional	adjustment,	
rest	periods	etc.)	as	it	was	beyond	the	scope	of	this	study,	and	in	many	cases	was	
not	recorded.	Many	of	these	factors	could	have	modified	the	likelihood	and	time	
to	subsequent	laminitis	episodes	following	the	first	diagnosis,	however	there	was	
no	reason	to	presume	systematic	differences	in	laminitis	treatment	between	the	
categories	of	independent	variables	included.	
	
The	use	of	equine	first-opinion	EMR	for	studies	of	this	type	is	feasible,	and	offers	
advantages	over	smaller	scale,	prospective	studies,	or	those	involving	only	
referral	populations.	It	does,	however,	pose	additional	challenges	and	has	some	
limitations	which	need	to	be	addressed	and	taken	into	account	if	study	validity	is	
to	be	accepted.	Data	errors	can	be	a	feature	of	any	study,	but	are	difficult	or	
impossible	to	rectify.	The	variable	nature	of	medical	records	also	means	that	
useful	information	is	often	missing,	either	systematically	(like	horse	weights),	or	
idiosyncratically.	Studies	focusing	on	prescription	information	may	offer	the	
most	accuracy	in	terms	of	sensitivity	of	categorisation,	due	to	the	automated	
nature	of	prescribing	and	billing,	but	will	likely	always	suffer	from	a	lack	of	dosing	
information	in	this	species	until	weighing	horses	accurately	becomes	easy	and	
commonplace.	Despite	these	limitations,	EMR	can	be	used	to	better	understand	
veterinary	decision-making,	and	to	help	untangle	complicated	disease	systems	
that	require	large	sample	sizes	for	their	estimation.	
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